In this Section |
231972 Do women change their diet after breast cancer diagnosis? An exploratory analysisMonday, November 8, 2010
Objective: To investigate whether the dietary patterns differ among women newly diagnosed with breast cancer and among long-term survivors.
Methods: Factor analysis was used to identify dietary patterns based on daily consumptions of 19 food groups. Women were categorized into different groups according to the interval between date of breast cancer diagnosis and date of dietary assessment. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Results: Two dietary patterns were identified: the “prudent” dietary pattern characterized by a high intake of fruits and vegetables and the “western” dietary pattern characterized by a high intake of energy-dense foods. The prudent diet was associated with a reduced breast cancer risk among women with diet assessed ≤ 1 year of cancer diagnosis (OR=0.89, 95% CI: 0.62-1.28) but an increased risk among women with diet assessed ≥ 3 years after diagnosis (OR=1.70, 95% CI: 1.04-2.77). The western diet was associated with an increased breast cancer risk among women with diet assessed ≤ 1 year of cancer diagnosis (OR=1.73, 95% CI: 1.12-2.65) but a reduced risk among women with diet assessed at 2 years after diagnosis (OR=0.69, 95% CI: 0.44-1.10). However, the western diet resumed a positive association with breast cancer among women with diet assessed ≥ 3 years after cancer diagnosis (OR=1.84, 95% CI: 1.05 -3.22). Conclusion: Women with newly diagnosed breast cancer tend to consume a healthy diet one or two years after cancer diagnosis but this trend did not continue among long-term cancer survivors.
Learning Areas:
Public health or related researchLearning Objectives: Keywords: Breast Cancer, Dietary Assessment
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: Delta Omega student nominee I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
Back to: 3070.0: Delta Omega Poster Session I
|